UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Trims Stake in Henry Schein, Inc. $HSIC

Key Points

• UBS AM reduced its stake in Henry Schein by 53.4%, selling 484,352 shares and holding 421,952 shares valued at approximately $28.9 million as of the latest SEC filing.
• Several institutional investors, including JPMorgan Chase and Burgundy Asset Management, have increased their stakes in Henry Schein, indicating ongoing interest in the company's stock despite recent sell-offs.
• Henry Schein's stock is currently rated as a "Hold" by analysts, with a consensus target price of $76.67 and a recent quarterly earnings report that missed expectations but showed revenue growth.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lowered its position in Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 53.4% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 421,952 shares of the company's stock after selling 484,352 shares during the quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned 0.35% of Henry Schein worth $28,899,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. JPMorgan Chase & Co. increased its holdings in shares of Henry Schein by 6.5% in the first quarter. JPMorgan Chase & Co. now owns 6,373,036 shares of the company's stock worth $436,489,000 after acquiring an additional 390,399 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Henry Schein by 4.8% during the first quarter. Dimensional Fund Advisors LP now owns 2,240,933 shares of the company's stock valued at $153,480,000 after purchasing an additional 103,384 shares during the last quarter. Burgundy Asset Management Ltd. boosted its position in Henry Schein by 33.9% during the first quarter. Burgundy Asset Management Ltd. now owns 2,235,429 shares of the company's stock valued at $153,105,000 after purchasing an additional 566,530 shares during the last quarter. Clarkston Capital Partners LLC raised its stake in Henry Schein by 0.4% in the first quarter. Clarkston Capital Partners LLC now owns 1,751,570 shares of the company's stock valued at $119,965,000 after buying an additional 7,345 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its stake in Henry Schein by 1.0% in the first quarter. Charles Schwab Investment Management Inc. now owns 1,203,676 shares of the company's stock valued at $82,440,000 after buying an additional 11,999 shares during the period. Institutional investors own 96.62% of the company's stock.

Henry Schein Stock Performance

Shares of HSIC stock traded down $0.69 during mid-day trading on Friday, reaching $67.86. 5,625,720 shares of the company's stock traded hands, compared to its average volume of 1,392,004. Henry Schein, Inc. has a 12 month low of $60.56 and a 12 month high of $82.49. The firm has a 50 day moving average price of $68.75 and a two-hundred day moving average price of $69.37. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.78 and a current ratio of 1.41. The firm has a market capitalization of $8.23 billion, a PE ratio of 21.89, a price-to-earnings-growth ratio of 2.26 and a beta of 0.86.

Henry Schein (NASDAQ:HSIC - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $1.10 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.19 by ($0.09). Henry Schein had a net margin of 3.05% and a return on equity of 14.36%. The business had revenue of $3.24 billion for the quarter, compared to the consensus estimate of $3.22 billion. During the same period in the previous year, the firm earned $1.23 EPS. The company's revenue was up 3.3% on a year-over-year basis. Henry Schein has set its FY 2025 guidance at 4.800-4.940 EPS. On average, research analysts forecast that Henry Schein, Inc. will post 4.74 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Leerink Partners set a $75.00 target price on Henry Schein in a research note on Monday, July 14th. Robert W. Baird reissued a "neutral" rating and set a $72.00 price objective (down previously from $82.00) on shares of Henry Schein in a report on Monday, July 14th. Baird R W lowered Henry Schein from a "strong-buy" rating to a "hold" rating in a research report on Monday, July 14th. UBS Group cut their target price on Henry Schein from $75.00 to $70.00 and set a "neutral" rating on the stock in a research note on Wednesday, August 6th. Finally, JPMorgan Chase & Co. lowered their target price on shares of Henry Schein from $80.00 to $76.00 and set an "overweight" rating on the stock in a report on Thursday, August 7th. Five investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average target price of $76.67.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.